MedTrace Logo

Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain

NCT01015235 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2011-09-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.

Conditions

  • Pain, Postoperative

Interventions

DRUG

Placebo

Subcutaneous infusion-once over 4 hours

DRUG

KAI-1678

Subcutaneous infusion-once over 4 hours

DRUG

Ketorolac Tromethamine

Active comparator, IV infusion, once

Sponsors & Collaborators

  • Trident Clinical Research Pty Ltd

    collaborator INDUSTRY

  • KAI Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gregory Bell, MD · KAI Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01015235 on ClinicalTrials.gov